The genome of each cell in the human body is constantly under assault from a plethora of
exogenous and endogenous processes that can damage DNA. If not successfully repaired …

Identifying colorectal cancer patient populations responsive to chemotherapy or
chemoradiation therapy before surgery remains a challenge. Recently validated mouse …

Simple Summary Breast cancer is the most common diagnosed malignancy and the main
leading cause of tumor-related death among women worldwide. Thus, several studies have …

Stratification of patients for targeted and immune-based therapies requires extensive
genomic profiling that enables sensitive detection of clinically relevant variants and …

Simple Summary DNA repair deficiency (DRD) is common in many cancers. This deficiency
contributes to pathogenesis of the disease, but it also presents an opportunity for therapeutic …

Tumor molecular profiling of single gene-variant ('first-order') genomic alterations informs
potential therapeutic approaches. Interactions between such first-order events and global …

The distinction between undifferentiated melanoma (UM) or dedifferentiated melanoma
(DM) from undifferentiated or unclassifiable sarcoma can be difficult and requires the careful …

Molecular tests assist at various stages of cancer patient management, including providing
diagnosis, predicting prognosis, identifying therapeutic targets, and determining hereditary …

The molecular characterization of tumors now informs clinical cancer care for many patients.
This advent of molecular oncology has been driven by the expanding number of therapeutic …

Lynch syndrome (LS) is a hereditary cancer syndrome that accounts for 3% of all new
colorectal cancer (CRC) cases. Patients carry a germline pathogenic variant in one of the …